IL-18 is an established biomarker of heart failure, so that it has been proposed that anti-IL-18 treatment may have therapeutic effects in patients with SCD at risk for cardiac arrhythmias and adverse outcomes (30). The gene discussed is IL18; the disease is cardiac arrhythmia.